Valneva Announces $42 Million IXIARO® Supply Contract with US Government
News Mar 16, 2016
Valneva SE has announced the signing of a $42 million contract with the US Government’s Department of Defense for the supply of its Japanese encephalitis (JE) vaccine IXIARO®. Under the terms of the agreement, Valneva will supply IXIARO® doses to the Defense Logistics Agency (DLA), Supply Center of the US Department of Defense for a total value of $42 million over a two-year period (a base year and an option year).
First deliveries are expected to commence in the coming weeks. JE is a very serious and growing public health threat in Asia. The US Department of Defense has been using IXIARO® to protect the near 360,000 U.S. military and civilian personnel, and their families, working and living in endemic countries since 2010.
Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva commented, “With a mortality rate that can reach 30% and neurological sequelae for half of the survivors1 , Japanese encephalitis is a clear danger to the thousands of military personnel - and their families - that are stationed in areas where the disease is endemic.
We feel honoured that the US Department of Defence continues to acknowledge our vaccine as the best protection against the disease". IXIARO® is the only JE vaccine approved in the US. Valneva, which successfully established its own global marketing & distribution network in the second half of 2015, now markets and distributes IXIARO® directly to the US military.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Personalized Tumor Vaccine Shows PromiseNews
A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018